|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2008-2-13
|
|
pubmed:abstractText |
Tamoxifen is still the most widely used drug in hormone therapy for the treatment of breast cancer. Its benefits in adjuvant treatment are well documented in controlled and randomized clinical studies, which have demonstrated an increase in disease-free intervals of patients with positive hormonal receptors. However, the mechanisms involved in endocrine resistance are not clear. Laboratory and clinical data now indicate that bi-directional molecular cross-talk between nuclear or membrane ER and growth factor receptor pathways may be involved in endocrine resistance. We recently found a functional interaction between alpha6beta4 integrin and ErbB-3 receptor to maintain the PI3K/Akt survival pathway of mammary tumour cells. We sought to improve understanding of this process in order to provide the involvement of both receptors insight into mechanism of Tamoxifen resistance.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-10579725,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-10744756,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-10963602,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-11156523,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-11212261,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-11252954,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-11438664,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-12105188,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-12554748,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-12845622,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-14745018,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-15027887,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-15569979,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-15613443,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-15661551,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-15661684,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-15864276,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-16168139,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-16258729,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-16322210,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-16322245,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-16622466,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-16740748,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-16901783,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-17308105,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-7591267,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-7850807,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-8096075,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-8408302,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-9048584,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-9344587,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-9428518,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-9516929,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-9677338,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-9823984,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18270579-9828250
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1932-6203
|
|
pubmed:author |
pubmed-author:AvetraniPaoloP,
pubmed-author:BonGiuliaG,
pubmed-author:BuglioniSimonettaS,
pubmed-author:Di CarloSelene ESE,
pubmed-author:FabiAlessandraA,
pubmed-author:FalcioniRitaR,
pubmed-author:FolgieroValentinaV,
pubmed-author:MelucciElisaE,
pubmed-author:MottoleseMarcellaM,
pubmed-author:NisticòCeciliaC,
pubmed-author:PerracchioLetiziaL,
pubmed-author:RosanòLauraL,
pubmed-author:SacchiAdaA,
pubmed-author:SperdutiIsabellaI,
pubmed-author:ViciPatriziaP
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
3
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
e1592
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:18270579-Biopsy,
pubmed-meshheading:18270579-Breast Neoplasms,
pubmed-meshheading:18270579-Cell Line, Tumor,
pubmed-meshheading:18270579-Disease-Free Survival,
pubmed-meshheading:18270579-Drug Resistance, Neoplasm,
pubmed-meshheading:18270579-Estrogen Receptor beta,
pubmed-meshheading:18270579-Female,
pubmed-meshheading:18270579-Humans,
pubmed-meshheading:18270579-Integrin alpha6beta4,
pubmed-meshheading:18270579-Oncogene Protein v-akt,
pubmed-meshheading:18270579-Receptor, erbB-3,
pubmed-meshheading:18270579-Receptor Cross-Talk,
pubmed-meshheading:18270579-Signal Transduction,
pubmed-meshheading:18270579-Tamoxifen
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas.
|
|
pubmed:affiliation |
Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
